TMCnet News
Deciphera Pharmaceuticals Presents Data Highlighting Kinase Inhibitor Pipeline including Proprietary and Partnered Programs at AACR 2015 Annual MeetingDeciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, today announced that preclinical data on the company's growing pipeline of next generation kinase inhibitors were presented at the American Association for Cancer Research (AACR) Annual Meeting 2015. The presentations include data on Deciphera's most advanced proprietary drug candidates including altiratinib, a potent and balanced inhibitor of MET/TRK/TIE2 and VEGFR2 kinases and rebastinib, a TIE2 inhibitor, and on the Company's work with Eli Lilly and Company on pan-RAF inhibitors. "We are excited to share the results from these studies of our novel kinase inhibitor drug candidates with the oncology community at AACR. These data demonstrate the unique attributes offered by our advanced small molecule kinase inhibitor therapeutics to block key cancer signaling mechanisms, preventing the ability of tumor cells to thrive and spread," said Michael D. Taylor, Ph.D., Deciphera's President and Chief Executive Officer. In a poster presentation entitled "Altiratinib is a potent inhibitor of TRK kinases and is efficacious in TRK-fusion driven cancer models," Deciphera researchers in collaboration with the Memorial Sloan Kettering Cancer Center demonstrated that altiratinib potently inhibited TPM3-TRKA and ETV6-TRKC fusion protein activation and cell proliferation in tumor cell lines. TRK kinases are implicated in a variety of cancers in which TRK gene fusions have been shown to drive tumor growth. Combined with its inhibition of key tumor microenvironment targets including MET, TIE2, and VEGFR2 kinases, altiratinib provides the potential to durably treat cancers in patients harboring these TRK fusions. Altiratinib is currently in a Phase 1 clinical trial in patients with solid tumors.
In a poster presentation entitled, "Mouse PDX trial suggests combination efficacy of Raf and EGFR inhibition for colorectal cancer with BRaf or KRas mutation," preclinical results were presented on LSN3074753, a pan-RAF inhibitor developed by Deciphera in collaboration with Lilly. This program is currently in Phase 1 clinical development. Synergy (News - Alert) was found in a subset of colorectal cancers by combining the pan-RAF inhibitor, which has been shown to inhibit mutant KRAS and BRAF tumor cell drivers that occur in approximately 70% of colorectal cancer patients, with the anti-EGFR antibody cetuximab.
About Deciphera Pharmaceuticals Deciphera Pharmaceuticals seeks to improve treatment for patients with cancer by designing kinase inhibitor therapies that target the hallmarks of cancer biology. We specifically design our small molecule compounds to simultaneously block multiple cancer signaling mechanisms in the tumor cell and the tumor microenvironment to prevent growth and spread. Deciphera's unique approach represents an important advance over current therapies in the durability of kinase inhibition and resiliency to genetic mutations to provide greater benefit across a range of cancers. Deciphera's business strategy is to advance its drug candidates for genetically defined cancers and cancers that target the tumor microenvironment through both proprietary and partnered programs. Deciphera's internal product pipeline includes altiratinib, a MET/TIE2/TRK/VEGFR2 kinase inhibitor currently in Phase 1 clinical development, a pan-KIT inhibitor (DCC-2618) currently in preclinical development and rebastinib, a TIE2 kinase inhibitor currently in Phase 1 clinical development. Our ultra-specific FMS inhibitor (DCC-3014), which blocks the actions of pro-tumoral macrophages in the tumor microenvironment, is currently in preclinical development. In addition, a pan-RAF inhibitor is currently in Phase 1 development with Lilly.
|